Literature DB >> 1452082

Plasma concentrations of endogenous heparinoids in portal hypertension.

R F McKee1, S Hodson, J Dawes, O J Garden, D C Carter.   

Abstract

Bleeding as a complication of liver disease can occur in the absence of recognised haemostatic defects. It is now possible to measure the concentration of endogenous heparinoid substances in the blood using a competitive binding assay. One such substance, heparan sulphate (normal range < 600 ng/ml) was assayed in the plasma of 49 patients admitted because of oesophageal varices. In 27 patients with recent upper gastrointestinal bleeding the median plasma heparan sulphate value was 1700 ng/ml (interquartile (IQ) range 900-3900) compared with 390 ng/ml (IQ range 256-800) in 22 patients with no recent bleed (p < 0.01). As heparan sulphate is metabolised by the same route as exogenous heparin, an attempt to establish a cause for the raised heparan concentrations was made by measuring the clearance of exogenous heparin in 10 portal hypertensive patients and 10 controls. The median half life of heparin in plasma in the portal hypertensive patients (25.5 minutes; IQ range 22-34) was significantly longer (p < 0.007) than the median half life in the controls (18.7 minutes; IQ range 17-21.5). Thus, there is evidence of raised concentrations of endogenous heparin like substances in portal hypertensive patients after gastrointestinal bleeding. These high concentrations may result from reduced hepatic clearance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452082      PMCID: PMC1379544          DOI: 10.1136/gut.33.11.1549

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

Review 1.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

2.  The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine.

Authors:  J Dawes; C V Prowse; D S Pepper
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

3.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

4.  Fibreoptic endoscopy and the use of the Sengstaken tube in acute gastrointestinal haemorrhage in patients with portal hypertension and varices.

Authors:  B H Novis; P Duys; G O Barbezat; J Clain; S Bank; J Terblanche
Journal:  Gut       Date:  1976-04       Impact factor: 23.059

5.  Bleeding after liver biopsy does not correlate with indices of peripheral coagulation.

Authors:  K Ewe
Journal:  Dig Dis Sci       Date:  1981-05       Impact factor: 3.199

6.  Heparin elimination in patients with liver cirrhosis.

Authors:  A N Teien
Journal:  Thromb Haemost       Date:  1977-10-31       Impact factor: 5.249

7.  Heparin response and clearance in acute and chronic liver disease.

Authors:  H Sette; R D Hughes; P G Langley; A E Gimson; R Williams
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

8.  Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder.

Authors:  R N Palmer; M E Rick; P D Rick; J A Zeller; H R Gralnick
Journal:  N Engl J Med       Date:  1984-06-28       Impact factor: 91.245

9.  A sensitive competitive binding assay for exogenous and endogenous heparins.

Authors:  J Dawes; D S Pepper
Journal:  Thromb Res       Date:  1982-08-15       Impact factor: 3.944

10.  Heparin pharmacokinetics: increased requirements in pulmonary embolism.

Authors:  T L Simon; T M Hyers; J P Gaston; L A Harker
Journal:  Br J Haematol       Date:  1978-05       Impact factor: 6.998

View more
  7 in total

Review 1.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

2.  Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity.

Authors:  Khue G Nguyen; Francis B Gillam; Jared J Hopkins; Srinivas Jayanthi; Ravi Kumar Gundampati; Guowei Su; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Barbara K Felber; Jian Liu; Suresh Kumar Thallapuranam; David A Zaharoff
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

3.  The circulating glycosaminoglycan signature of respiratory failure in critically ill adults.

Authors:  Eric P Schmidt; Guoyun Li; Lingyun Li; Li Fu; Yimu Yang; Katherine H Overdier; Ivor S Douglas; Robert J Linhardt
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

4.  Endogenous Heparin-Like Substances May Cause Coagulopathy in a Patient with Severe Postpartum Hemorrhage.

Authors:  Shichun Wang; Chao Qi; Zhicheng Liu; Ting Xu; Chunyan Yao
Journal:  Transfus Med Hemother       Date:  2019-12-05       Impact factor: 3.747

5.  Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients.

Authors:  Marco Ranucci; Ekaterina Baryshnikova; Giuseppe Isgrò; Concetta Carlucci; Mauro Cotza; Giovanni Carboni; Andrea Ballotta
Journal:  Crit Care       Date:  2014-09-05       Impact factor: 9.097

6.  Graft glycocalyx degradation in human liver transplantation.

Authors:  Arie Passov; Alexey Schramko; Heikki Mäkisalo; Arno Nordin; Sture Andersson; Eero Pesonen; Minna Ilmakunnas
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

7.  Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation.

Authors:  Marco Senzolo; Seema Agarwal; Paola Zappoli; Sushang Vibhakorn; Susan Mallett; Andrew K Burroughs
Journal:  Liver Int       Date:  2009-02-09       Impact factor: 5.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.